An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 211243
Company: JANSSEN PHARMS

Medication Guide

REMS

Products on NDA 211243

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
SPRAVATO	ESKETAMINE HYDROCHLORIDE	EQ 28MG BASE	SPRAY;NASAL	Prescription	None	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 211243

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/05/2019	ORIG-1	Approval	Type 2 - New Active Ingredient	PRIORITY	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211243Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/18/2023	SUPPL-12	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211243s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211243Orig1s012ltr.pdf
01/03/2022	SUPPL-6	REMS - MODIFIED - D-N-A	Letter (PDF) Review (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211243Orig1s006ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211243Orig1s006.pdf
07/31/2020	SUPPL-4	Efficacy-New Indication	Label (PDF) Letter (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211243Orig1s004ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/211243Orig1s004.pdf
02/11/2020	SUPPL-3	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211243Orig1s003ltr.pdf
06/25/2019	SUPPL-2	REMS - MODIFIED - D-N-A	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211243Orig1s002ltr.pdf
05/09/2019	SUPPL-1	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211243Orig1s001ltr.pdf

Labels for NDA 211243

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/18/2023	SUPPL-12	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211243s012lbl.pdf
07/31/2020	SUPPL-4	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf
02/11/2020	SUPPL-3	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s003lbl.pdf
05/09/2019	SUPPL-1	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243s001lbl.pdf
03/05/2019	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf

Top